Despite positive results after phase 2 of clinical trials for its messenger RNA vaccine, the Sanofi laboratory decided not to continue its development, judging that marketing would be too late. Its American competitor Pfizer launched a clinical trial on Monday for its pill supposed to prevent the risk of infection.
- Sanofi is pursuing phase 3 of its other vaccine, based on a recombinant protein.
- Pfizer’s treatment reduces the risk of infection in the relatives of an infected person and prevents serious symptoms in the infected person.
Two rooms, two atmospheres. In France, the Sanofi laboratory has announced that it is abandoning phase 3 of clinical trials on its messenger RNA anti-Covid vaccine despite encouraging phase 1 and 2 results. Sanofi judges that it would arrive too late on the market, when 12 billion doses of vaccines will have been produced in total by the end of the year.
The other vaccine planned for the end of the year
If Sanofi abandons its RNA vaccine, the laboratory continues phase 3 of its other vaccine, based on a recombinant protein. This, combined with an adjuvant, “stimulates your immune system and subjects it to the protein of the virus, which makes you react, said Olivier Bogillot, the president of Sanofi, last July. This is what we use for flu vaccination, a proven technology that we have been using for a few years […]before the arrival of messenger RNA.” Developed with the British GSK, the results are expected before the end of 2021.
Trials of Pfizer’s anti-Covid pill have begun
At the same time, the American Pfizer is continuing to develop its anti-Covid pill. Its objective is to reduce the risk of infection among the relatives of an infected person. It works by preventing the virus from replicating in the host’s body. This could both prevent the infected person from suffering severe symptoms and those close to them from developing the disease. “We think this treatment could help stop the virus very early, before it has a chance to replicate widely, potentially preventing symptomatic cases of disease in those who have been exposed and slowing the onset of infection in others”, said Mikael Dolsten, scientific director of Pfizer.
This Monday, the group announced that it was starting a large-scale clinical trial. This treatment, dubbed PF-07321332, could prove to be very useful in the fight against the virus and “complementary”Vaccines, advanced Mikael Dolsten.
.
